DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.27%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$423M
AUM Growth
+$423M
(+1.1%)
Cap. Flow
-$19.4M
Cap. Flow
% of AUM
-4.58%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5
Top Buys
| 1 |
Lexeo Therapeutics
LXEO
|
$2.27M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$1.57M |
| 3 |
IDEAYA Biosciences
IDYA
|
$1.56M |
| 4 |
Ascendis Pharma
ASND
|
$1.28M |
| 5 |
Structure Therapeutics
GPCR
|
$1.27M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.9M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$4.3M |
| 3 |
Viking Therapeutics
VKTX
|
$4.02M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$2.51M |
| 5 |
TSVT
2seventy bio
TSVT
|
$1.99M |
Sector Composition
| 1 | Healthcare | 86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Neurogene
NGNE
$284M
| $326K | 0.08% |
7,775
-3,225
| -29% | -$135K |
|
|
ADAP
77
Adaptimmune Therapeutics
ADAP
$13.9M
| $324K | 0.08% |
341,064
| – | – |
|
78
Alto Neuroscience
ANRO
$97.7M
| $306K | 0.07% |
26,786
-93,214
| -78% | -$1.07M |
|
79
Neuronetics
STIM
$216M
| $238K | 0.06% |
313,717
| – | – |
|
80
Compass Therapeutics
CMPX
$466M
| $215K | 0.05% |
116,882
| – | – |
|
|
NVRO
81
DELISTED
NEVRO CORP.
NVRO
| $212K | 0.05% |
38,000
+10,000
| +36% | +$55.9K |
|
82
Spero Therapeutics
SPRO
$117M
| $168K | 0.04% |
125,000
| – | – |
|
83
Karyopharm Therapeutics
KPTI
$61.4M
| $160K | 0.04% |
12,845
| – | – |
|
|
MORF
84
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-231,748
| Closed | -$7.9M |
|
|
SYRS
85
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-135,850
| Closed | -$701K |
|
86
Terns Pharmaceuticals
TERN
$651M
| – | – |
-86,000
| Closed | -$586K |
|
87
Procept Biorobotics
PRCT
$2.11B
| – | – |
-13,994
| Closed | -$855K |
|
88
Oric Pharmaceuticals
ORIC
$1.03B
| – | – |
-36,000
| Closed | -$255K |
|